A novel miR-4536-3p inhibition ameliorates Alzheimer’s disease by reducing Aβ accumulation and tau phosphorylation
miR-4536-3p inhibition offers a promising therapeutic strategy for AD by restoring the DBN1 expression, reducing neurodegeneration, and improving cognitive outcomes through PI3K/Akt pathway modulation.
Authors
- Byeong C. Kim (ORCID: https://orcid.org/0000-0001-6827-6730)
- Dohee Kim
- Han‐Seong Jeong (ORCID: https://orcid.org/0000-0001-6921-6625)
- Jiyun Choi (ORCID: https://orcid.org/0009-0008-7935-3736)
- Jinsu Hwang (ORCID: https://orcid.org/0009-0008-0672-3601)
- Haewon Jeong (ORCID: https://orcid.org/0009-0008-3254-4834)
- Hyong‐Ho Cho (ORCID: https://orcid.org/0000-0002-1331-4039)
- Sujeong Jang (ORCID: https://orcid.org/0000-0001-8673-7887)
- Su-Jin Han (ORCID: https://orcid.org/0000-0002-0876-1352)
- Mahesh Ramalingam (ORCID: https://orcid.org/0000-0002-8831-4375)
Institutions
- Chonnam National University (KR)
- Chonnam National University Hospital (KR)
- Korea Testing & Research Institute (KR)
Publication Details
- Journal
- Alzheimer s Research & Therapy
- Published
- 2025-08-12
- DOI
- https://doi.org/10.1186/s13195-025-01834-3
- Citations
- 1
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- National Research Foundation
- Chonnam National University
- Ministry of Trade, Industry and Energy
- Korea Institute for Advancement of Technology
- Korea Health Industry Development Institute
- National Research Foundation of Korea